0000000000199346
AUTHOR
Carmen G. Gonzalez
Body weight variation and control of cardiovascular risk factors in essential hypertension.
The objective was to assess the impact of weight changes on blood pressure (BP), lipids and glucose goals in a cohort of hypertensive subjects.Prospective follow-up.Hypertension clinic.326 hypertensive non-diabetic subjects, 46% with metabolic syndrome (MS).Usual care treatment, which included diet, physical exercise and drugs prescribed when indicated. All patients were observed for up to 1 year.BP and low-density lipoprotein-cholesterol (LDL-C) goal were those in ESH/ESC and ATP III recommendations, respectively. The glucose goal was to delay progression to type 2 diabetes mellitus, or to achieve blood glucose100 mg/dl for non-diabetics. According to body weight changes, patients were cat…
Regression of left ventricular hypertrophy and microalbuminuria changes during antihypertensive treatment.
The objective of the present study was to assess the regression of left ventricular hypertrophy (LVH) during antihypertensive treatment, and its relationship with the changes in microalbuminuria.One hundred and sixty-eight previously untreated patients with echocardiographic LVH, 46 (27%) with microalbuminuria, were followed during a median period of 13 months (range 6-23 months) and treated with lifestyle changes and antihypertensive drugs. Twenty-four-hour ambulatory blood pressure monitoring, echocardiography and urinary albumin excretion were assessed at the beginning and at the end of the study period.Left ventricular mass index (LVMI) was reduced from 137 [interquartile interval (IQI)…
Determinants of urinary albumin excretion reduction in essential hypertension: A long-term follow-up study.
The objective of the present study was to assess factors related to long-term changes in urinary albumin excretion (UAE) of nondiabetic microalbuminuric (n = 252) or proteinuric hypertensive individuals (n = 58) in a prospective follow-up.After enrollment, patients were placed on usual care including nonpharmacological treatment and/or treatment with an antihypertensive drug regime to achieve blood pressure135/85 mmHg. Periodic UAE measurements were performed until regression or significant reduction (defined when UAE dropped50% from the initial values, plus reduction of UAE to30 mg/24 h for microalbuminuric patients and300 mg/24 h for proteinuric patients).Among the microalbuminuric patien…
Objetivos terapéuticos del colesterol LDL y cambios de la proteína C reactiva en pacientes de alto riesgo coronario
Resumen Fundamentos y objetivo Valorar los efectos de la asociacion de ezetimiba y estatina (terapia combinada), respecto a duplicar la dosis de estatina, a la hora de alcanzar los objetivos terapeuticos de colesterol ligado a las lipoproteinas de baja densidad (c-LDL) y en la variacion de la proteina C reactiva (PCR). Pacientes y metodos Estudio longitudinal retrospectivo de pacientes con dislipemia en tratamiento con estatina y control lipidico insuficiente. Se incluyeron 111 pacientes; a 59 se les duplico la dosis de estatina previa y a 52 se les anadio ezetimiba a la estatina (terapia combinada). Se calcularon las diferencias en lipidos y la proteina C reactiva. Resultados La terapia co…